Safety
Compounded peptide safety: pharmacy, sourcing and red flags
Are compounded peptides safe? 503A vs 503B explained from FDA, what the HHS interim policy requires, questions to ask a program, MedWatch reporting and red flags.
By Julian Caraulani · Updated October 30, 2026 · Reviewed by Dr. A. Goher, MBBS
Compounded peptides are only as safe as the pharmacy, the ingredient and the prescriber behind them. FDA says "Compounded drugs are not FDA-approved" and that it does not review them for safety, effectiveness or quality before they reach patients (FDA). Ask any program which pharmacy fills the order and how the ingredient was tested. Licensed programs start at $57 a month.
Below: how 503A pharmacies differ from 503B outsourcing facilities, what the HHS interim peptide policy of 28 October 2026 requires, the questions to ask before you pay, how to report a problem, and the red flags that should stop you. Status checked 30 October 2026. The policy is interim and can be withdrawn.
Why pharmacy quality matters
Compounding means a pharmacist mixes or alters ingredients to make a drug for one patient. When it goes wrong, the harm can be large. FDA notes that in 2012 contaminated drugs from one Massachusetts pharmacy "led to more than 750 cases of infection and more than 60 deaths of patients in 20 states" (FDA, Human Drug Compounding Laws). That outbreak led Congress to pass the Drug Quality and Security Act in 2013, which created the 503B category.
FDA also warns that "poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient" (FDA, Compounding Q&A). For injectable peptides, sterility and endotoxin control matter most, because an injection bypasses the body's outer defenses.
503A vs 503B: what the difference means
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A state-licensed pharmacy (or federal facility, or physician) compounding for individual patients | A facility that has elected to register with FDA as an outsourcing facility |
| Prescription | Requires a valid patient-specific prescription | May fill patient-specific prescriptions or provider orders for office stock |
| Manufacturing standard | Not subject to federal CGMP, though USP and state rules apply | Must comply with CGMP |
| Main inspector | State board of pharmacy, with FDA surveillance and for-cause inspections | FDA, on a risk-based schedule |
| Adverse event reporting | Varies by state; required for products under the HHS peptide policy | Required |
| Covered by the HHS peptide policy | Yes, for six peptides under conditions | No: the policy names only 503A compounders |
Sources for the table: FDA says outsourcing facilities "must comply with CGMP requirements; are inspected by FDA according to a risk-based schedule" (FDA, Information for Outsourcing Facilities). For 503A pharmacies, FDA says "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities" (FDA, Compounding Q&A). FDA publishes a list of registered outsourcing facilities.
Neither type makes a compounded drug FDA-approved. A 503B label means stricter manufacturing rules, not proof that a peptide works.
Price checked Oct 30 · Cancel anytime · Medication included · No email needed
What the HHS interim policy requires
On 28 October 2026, HHS said it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A" (Federal Register 2026-22192). Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The full policy, which we read in a browser on 30 October 2026 because hhs.gov blocks automated readers, sets conditions that all must be met:
| Condition | What it means for you | Source |
|---|---|---|
| Peptide and route on the list | Each peptide is limited to set routes, for example KPV topical or oral only | HHS policy |
| Registered ingredient maker | The original manufacturer "is registered with FDA under section 510", complies with CGMP, and its facility address is on the certificate | HHS policy |
| Certificate of analysis | Testing for identity, purity, potency and contaminants such as endotoxins, heavy metals and microbes | HHS policy |
| One active ingredient | No blends or combination vials | HHS policy |
| Reporting | Compounders report serious adverse events and quality issues to FDA MedWatch and to the states involved | HHS policy |
| Label statement | "This is a compounded drug product. Not for resale." | HHS policy |
| Oral forms | The pharmacy keeps documentation that the oral formulation is absorbed adequately in humans | HHS policy |
| Devices | Only an FDA 510(k)-cleared syringe may be packaged with it | HHS policy |
| Prescription | A patient-specific prescription, compounded under sanitary conditions | HHS policy |
HHS also states it "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises" (Federal Register). The policy does not bind state boards, and some states may still restrict these peptides. Our HHS peptide policy guide and peptide legal status tracker have the timeline.
What to ask a program before you pay
- Which pharmacy fills my prescription? Get the legal name, not a brand name.
- Is it a 503A pharmacy or a 503B outsourcing facility? For the six peptides in the HHS policy, it should be a 503A pharmacy.
- Is the pharmacy licensed in my state? Check the license number with your state board of pharmacy, and use FDA's BeSafeRx page to look up state-licensed online pharmacies.
- Can I see the certificate of analysis for the ingredient lot? Under the policy it should name the original manufacturer and its facility address.
- Is the program LegitScript certified? You can check a website on LegitScript's certification page. Certification is a screening signal, not proof of product quality.
- Who reviews my intake, and are labs included? A clinician should screen you before anything ships.
- How do I report a reaction? The label should explain how.
Several programs we list do not name their pharmacy on their public pages; we record that as a gap on each program review rather than guess.
How to report a problem: MedWatch and your state board
FDA's MedWatch program takes reports from patients as well as clinicians. FDA says "MedWatch receives reports from the public and when appropriate, publishes safety alerts" (FDA MedWatch). Report a serious reaction, a product that looks wrong (cloudy, discolored, particles) or a label that does not match what you were prescribed. Also tell the prescriber and the pharmacy. A complaint about a 503A pharmacy can go to the board of pharmacy in the state where it is licensed.
Red flags
- The seller calls a compounded peptide "FDA approved" or "FDA cleared". It is not.
- No prescriber, no intake and no named pharmacy.
- Vials labeled "research use only" or "not for human use".
- Dosing calculators, mixing kits or diluent water sold alongside the product, which FDA has cited in warning letters (see research vs prescription peptides).
- Blends of two or more peptides in one vial, which fall outside the HHS policy.
- A peptide or route not on the HHS list, such as injectable KPV.
- No way to reach a clinician after you start.
If a site shows several of these, check it with our scam checker before you enter any details.
FAQ
Are compounded peptides safe?
Safety depends on the pharmacy, the ingredient and the prescriber. Compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality before they reach patients. Human evidence for peptides such as BPC-157 is also very limited. A licensed 503A pharmacy using a tested ingredient from an FDA-registered maker lowers quality risks but does not prove benefit.
What is the difference between 503A and 503B?
A 503A pharmacy is state-licensed and compounds for individual patients on a prescription, overseen mainly by its state board. A 503B outsourcing facility registers with FDA, must follow CGMP manufacturing rules and is inspected by FDA on a risk-based schedule. The HHS peptide policy covers 503A compounders only, not 503B facilities.
What does a certificate of analysis show?
A certificate of analysis reports lab tests on a specific ingredient lot. Under the HHS peptide policy it should show identity, purity, potency and tests for contaminants such as endotoxins, heavy metals and microbes, and name the original manufacturer and its facility address. Ask the program whether its pharmacy will share the certificate for your lot.
Does LegitScript certification mean a peptide is safe?
No. LegitScript certification shows a website passed a compliance review that ad platforms and payment processors rely on. It says nothing about whether a specific peptide works or whether a given vial is pure. Treat it as one screening signal alongside a named, state-licensed pharmacy and a clinician who reviews your history.
Who oversees compounding pharmacies?
State boards of pharmacy have primary day-to-day oversight of state-licensed 503A pharmacies, with FDA conducting surveillance and for-cause inspections. FDA primarily oversees 503B outsourcing facilities. The HHS peptide policy adds reporting to FDA and to the states involved for the six covered peptides, but it does not override state rules.
Where do I report a side effect from a compounded peptide?
Use FDA MedWatch, which accepts reports from patients and the public as well as clinicians. Tell the prescriber and the pharmacy too, and keep the vial and its label. For a pharmacy problem, contact the board of pharmacy in the state where the pharmacy is licensed. Seek urgent care for signs of a serious reaction.
Compare licensed prescription programs on oversight and price on our best peptide programs page, or see every plan on the price table.